TrialNature communications2024

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.

Salvatore Siena et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.